Format

Send to

Choose Destination
Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Author information

1
Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, Utah.
2
Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah.
3
Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
4
University of Utah School of Medicine, Salt Lake City, Utah.
5
Department of Biology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
6
Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, Utah. Department of Biology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
7
Center for Investigational Therapeutics at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Division of Medical Oncology, University of Utah School of Medicine, Salt Lake City, Utah.
8
Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, Utah. Center for Children's Cancer Research at Huntsman Cancer Institute, Salt Lake City, Utah. Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, Utah. stephen.lessnick@hci.utah.edu.

Abstract

PURPOSE:

Ewing sarcoma is a pediatric bone tumor that absolutely relies on the transcriptional activity of the EWS/ETS family of fusion oncoproteins. While the most common fusion, EWS/FLI, utilizes lysine-specific demethylase 1 (LSD1) to repress critical tumor suppressors, small-molecule blockade of LSD1 has not yet been thoroughly explored as a therapeutic approach for Ewing sarcoma. We therefore evaluated the translational potential of potent and specific LSD1 inhibition with HCI2509 on the transcriptional program of both EWS/FLI and EWS/ERG as well as the downstream oncogenic phenotypes driven by EWS/ETS fusions in both in vitro and in vivo models of Ewing sarcoma.

EXPERIMENTAL DESIGN:

RNA-seq was used to compare the transcriptional profiles of EWS/FLI, EWS/ERG, and treatment with HCI2509 in both EWS/FLI- and EWS/ERG-containing cell lines. We then evaluated morphologic phenotypes of treated cells with immunofluorescence. The induction of apoptosis was evaluated using caspase-3/7 activation and TUNEL staining. Colony forming assays were used to test oncogenic transformation and xenograft studies with patient-derived cell lines were used to evaluate the effects of HCI2509 on tumorigenesis.

RESULTS:

HCI2509 caused a dramatic reversal of both the up- and downregulated transcriptional profiles of EWS/FLI and EWS/ERG accompanied by the induction of apoptosis and disruption of morphologic and oncogenic phenotypes modulated by EWS/FLI. Importantly, HCI2509 displayed single-agent efficacy in multiple xenograft models.

CONCLUSIONS:

These data support epigenetic modulation with HCI2509 as a therapeutic strategy for Ewing sarcoma, and highlight a critical dual role for LSD1 in the oncogenic transcriptional activity of EWS/ETS proteins.

PMID:
24963049
PMCID:
PMC4155010
DOI:
10.1158/1078-0432.CCR-14-0072
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center